The neurofibromatoses are genetic disorders. NF1 and NF2 are each caused by a mutation in a known specific gene. The quest to understand how these disorders originate and progress (their pathogenesis) received a significant boost when researchers identified the causative genes. The leading theories about the pathogenesis of NF1 and NF2 are discussed in this chapter. Because the search for the biological cause of schwannomatosis was still underway when this book went to press, less is known about its pathogenesis (see Chapter 12) .
N A Search for Answers
In 1990, two groups of scientists working separately located the NF1 gene on chromosome 17 and characterized its protein product, neurofibromin. [1] [2] [3] In 1993, another two teams working separately identified the NF2 gene on chromosome 22; one named its protein "merlin" 4 and the other "schwannomin." 5 Once the genes were identified, work could begin on better understanding how mutations lead to tumor formation and other manifestations.
The search for answers, however, has been daunting. There is probably no single answer to the question, What causes NF1 and NF2? Just as these disorders cause various types of manifestations, so too there appear to be multiple molecular mechanisms at work.
When trying to understand the pathogenesis of a disorder, scientists may combine two techniques that approach the question from different directions. The traditional phenotypical approaches analyze the physical manifestations of the disorders, such as what cells are involved and how they function, and then work backward to determine what gene might cause these abnormalities. The genotypical approach tries to understand how genes function normally and how mutations lead to the physical manifestations of disease.
Many advances in knowledge about neurofibromatosis have occurred as a result of these scientific methods, but much more remains to be learned. Both the NF1 and NF2 genes are large, complex, and prone to mutation. The NF1 gene has one of the highest mutation rates of all genes. 6 Even so, this is an exciting time in the field of neurofibromatosis. As research yields additional insights into the pathogenesis of NF1, NF2, and schwannomatosis, diagnosis and treatments will improve.
N Two Genes with Similar Functions
When the NF1 and NF2 genes were first identified, both were classified as tumor suppressors. Although such genes are probably best known for their ability to prevent tumors from forming, their primary role in the body is to regulate cell growth and division. In the years since the NF1 and NF2 genes were discovered, scientists have learned more about not only how they regulate cell growth, but also the additional functions they perform in the body.
Cells divide and proliferate by following an orderly and highly regulated process known as the cell cycle. The process is initiated by mitogenic signals (from the word mitosis, or division), which function a bit like onand-off switches. When it receives such a signal, the cell initiates the cycle and copies its chromosomes, chemical structures that contain genes. After repairing any genetic errors, the cell then divides into two identical cells. When this process breaks down, cells divide out of control, crowding out other cells and forming tumors.
Oncogenes are normal cellular genes that when mutated can initiate this type of abnormal growth. These genes, which help cause a variety of cancers, act in a dominant fashion. Just one mutation, or genetic "hit," is enough to initiate the growth of a cancerous tumor. People with neurofibromatosis already have one malfunctioning gene at birth. Yet it may take years for tumors to develop, and these only rarely progress to malignancy.
Scientists decided that the neurofibromatosis genes, therefore, seemed to conform to Alfred Knudson's "two-hit theory" about tumor suppressors ( Fig. 3-1 ). Knudson developed this hypothesis when describing the disease process that leads to retinoblastoma, a rare childhood cancer affecting the retina of the eye. 7, 8 Retinoblastoma does not occur in neurofibromatosis; the two disorders are caused by different genes. Even so, the gene responsible for retinoblastoma (the Rb gene) formed the paradigm of the tumor suppressor model, which applies to both the NF1 and NF2 genes.
Although both the NF1 and NF2 genes function as tumor suppressors, they may inhibit cellular proliferation through different mechanisms. The NF1 gene normally suppresses cell growth directly by regulating the response to mitogenic signals. The NF2 gene works less directly, by regulating the function of signals sent between cells, and from cells to the surrounding matrix, which also inhibits or encourages cell proliferation. Both genes may also be modified or enhanced by hormones and the interaction with other genes, although this is an area deserving a great deal of rigorous study.
N Basic Genetics
NF1 and NF2 are both autosomal dominant disorders. Understanding what this means, and how these disorders develop, requires a basic knowledge of medical genetics. A brief introduction for the layperson is provided below. For information about why there is a 50/50 chance of passing NF1 and NF2 on to offspring, see Chapter 4. 
What Genes Do
Each cell in the body contains 23 pairs of chromosomes. One member of a pair of chromosomes is inherited from the mother and the other from the father. Chromosomes 1 through 22 are known as autosomal chromosomes, and are the same in males and females. NF1 and NF2 are autosomal disorders because their genes are located on one of the autosomes. Chromosomes in the 23rd pair are known as the sex chromosomes (XX for females; XY for males).
Chromosomes are located in the cell's nucleus, which functions much like a command center that sends instructions to the rest of the cell. When genes are activated or expressed, they produce proteins that determine everything from physical characteristics, such as hair color, to less obvious traits, such as susceptibility to disease. Genes do this by providing molecular blueprints for proteins that perform various tasks. The blueprint is in the form of a unique sequence of DNA, the basic chemical building blocks of heredity ( Fig. 3-2) .
Some genes are dominant and some are recessive-a concept first established by Gregor Mendel, the 19th century monk whose experiments with plants led to his landmark discovery of patterns of heredity. (Mendel wondered why a tall plant cross-bred with a small plant did not produce offspring of medium height. That led to the insight that certain inherited traits were dominant. The way those traits are passed on through genes would not be discovered until the next century.) Although each person has two copies of every gene, it takes two recessive genes to produce a trait, but just one dominant gene. Both NF1 and NF2 are caused by a change in a dominant gene.
How Genes Mutate
Whenever a cell divides, it first makes a complete copy of its DNA to pass on to the daughter cell ( Fig. 3-3 ). Mutations can occur at any time during cell division, due to a simple copying error. Or an outside mutagen (something that can cause a mutation) such as a toxin might injure a cell's DNA. However it happens, the mutation then gets passed on the next time the cell divides. When a DNA sequence changes because of a mutation, the genetic code gets scrambled. As a result, part of the instructions for the protein may be missing, or they may be arranged out of order. This causes some abnormality in the gene product. A truncated protein, for instance, does not contain all the necessary "ingredients" and functions poorly. At other times the protein cannot be made at all, or contains the wrong amino acid.
Researchers working on the Human Genome Project estimate that people have a total of 30,000 to 40,000 genes. 9 Because people inherit two copies of each gene, this means the nucleus of each cell contains about as many genes as there are words in this book. Both NF1 and NF2 develop from a mutation in just one gene (or, to use an analogy, an error in just one word in this book), which may then be exacerbated by mutations in additional "modifying" genes. The original error might be as small as the substitution of one chemical base for another in the genetic code (similar to a mistyped letter in one of the words you are reading), or as large as the deletion of the entire gene (similar to a single missing word).
From Genetic Error to Disorder
There are thousands of proteins in the body, which interact with one another to regulate basic cellular processes. When a genetic mutation causes one protein to malfunction, it can set off a domino-like chain reaction that affects other genes and proteins as well. Eventually this may cause manifestations of a disorder, such as tumor formation in neurofibromatosis. To determine the multiple biochemical steps between a single genetic error and the multiple manifestations of neurofibromatosis, scientists study signaling pathways-the sequence of individual genes and proteins (the dominos, if you will) that are activated or deactivated by the NF1 and NF2 genes.
To do this, scientists sometimes study actual tumor tissue taken from people with NF1 or NF2, which is then examined for telltale signs of genetic mutation. Another method is to conduct studies of living cells grown in the laboratory from donated samples (the in vitro approach). Or researchers may devise experiments in vivo, in living models of the disease, such as mice or fruit flies.
Generally scientists employ two techniques to better understand a gene's function. One method is to overexpress it so that it causes more dramatic, and thus more easily observed, effects than if it were expressed normally. Another approach is to create knockout models, animals or lower organisms that are genetically engineered to lack function of one or both copies of a gene. This enables researchers to determine what happens when one or both copies of the gene are absent. Both methods provide clues about the gene's normal function and what happens when it is mutated.
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NF1 Gene Structure and Mutations
The NF1 gene ( Fig. 3-4 ) consists of ~335,000 chemical bases, 10 making it one of the largest genes in the human body. Three of the gene's coding regions, known as exons, are alternatively spliced, [11] [12] [13] meaning that sometimes they are spliced in or out of the final translated sequence. This creates a slightly different protein or isoform. This is a fairly typical feature of genes and probably enables them to take on different functions in various areas of the body. The NF1 gene also contains three "nested" but separate genes-known as EVI2A, EVI2B, and OMGP-that are embedded into one of its noncoding introns.
14(p120) The function of these embedded genes is not known. Initially scientists speculated that they might have some effect on the manifestations of NF1 and might even help explain why manifestations can vary so greatly in people with the disorder. However, research in this area has been inconclusive so far.
Many different types of mutations, probably more than 500 at this point, have been identified in the NF1 gene. The exact mutation usually differs from one person to the next, and only in a small number of cases have identical mutations been identified.
Categories of mutations identified to date are listed in Table 3 -1. Most of the mutations result in gross truncation (a shorter-than-normal version) of neurofibromin. 15 Whatever the type of NF1 mutation, neurofibromin is either defective or available in such small quantities that it can't do its job correctly.
NF1 Gene Expression
Little is known at this point about what factors activate NF1 gene expression, 16(p601) but its protein product neurofibromin is expressed in several different cells throughout the body. The strongest expression is in cells of the nervous system, 16(p593) including neurons and glial cells such as Schwann cells, oligodendrocytes, and astrocytes 17 (see Chapter 2). Neurofibromin is also expressed in cells derived from the neural crest, a structure that is created early in embryonic development and eventually gives rise to pigment cells in the skin, bone, and some components of the peripheral nervous system. Melanocytes, for instance, produce skin pigmentation. Many nervous system and neural crest cells, of course, are also those that develop abnormalities in people with NF1. 
Impact on the Cell Cycle
The two prevailing theories about the pathogenesis of NF1 have something in common: that loss of the gene's protein product somehow disrupts the normal sequence of signals responsible for controlling cell division. To appreciate how even subtle errors in molecular signaling pathways can wreak such havoc, it is important to understand the basics of the cell cycle, which initiates and controls cell division. The cell cycle is an orderly four-step process that ends when the cell divides into two daughter cells. The cycle is regulated by a network of signaling molecules that respond to information both within and outside the cell. To use a familiar analogy, these signaling molecules are the biological versions of air traffic controllers. Some molecules monitor the status of a cell (similar to keeping an eye on a single plane); others monitor the environment (the sky or the runway). A series of signals are sent for the cell to divide (or the plane to land) only when the cell is ready and the conditions right (landing gear down, and runway clear). Otherwise, the cell will receive another set of signals that act as brakes that stop the cycle at 30 Neurofibromatosis Neurofibromin appears to act as a molecular brake, which is why its loss enables the cell to proliferate out of control.
NF1 Gene Signaling Pathways
Researchers are still trying to determine all of neurofibromin's functions. Part of the challenge is the sheer size of the protein.
Another is the complexity and interdependence of cells in the nervous system, which makes it difficult at times to determine which manifestations of NF1 are caused by loss of neurofibromin and which are caused by other factors. A third challenge is developing models in animals and lower organisms that mimic manifestations of NF1. Mice genetically engineered to have one functioning and one defective NF1 gene, to mimic the genetics of the disorder, do not develop tumors typical of NF1. Experiments in chimeric mice, bred to contain a defective NF1 gene as well as other features of the disorder, are helping researchers to create more accurate animal models of the disorder. Also useful are "conditional knockout" mice, in which both copies of the NF1 gene can be switched off by the investigator. In spite of these challenges, researchers have gained much insight into neurofibromin's functions by tracing the series of biochemical events that are triggered when the NF1 gene is expressed. This has helped researchers to learn what happens when the gene is mutated.
The Ras-GAP Pathway
The prevailing theory about how neurofibromin functions in the body is that it behaves like a guanosine triphosphatase (GTPase)-activating protein (GAP). Members of the GAP family regulate other proteins, including one known as Ras, which is the specific target for neurofibromin GAP activity. There are more than 50 members in the Ras family, 14(p126) and these proteins are best known for their role in initiating cell proliferation. 18(p14) Several studies suggest that Ras also has a role in cell differentiation-the process by which cells develop specialized functions. 19, 20 This means that neurofibromin interaction with Ras may have an impact not only on tumor growth but also on basic development. 16(p594) Researchers first suspected that neurofibromin might regulate Ras when they noticed that a small segment of the NF1 gene resembles the sequence of genes in the GAP family. 21(p748) Several functional studies have shown that neurofibromin does indeed regulate Ras. 16 (p593) Neurofibromin serves to act as a brake on cell proliferation, whereas Ras functions more as a gas pedal. The two are constantly in play to keep cell growth and proliferation balanced and under control. But when the NF1 gene is mutated, there is not enough neurofibromin to counter the actions of Ras. The result is out-of-control cell growth and tumor formation (Fig. 3-5) .
Ras activation, and neurofibromin regulation, may be involved in more than tumor formation. Recent research also indicates that Ras overexpression in the brain may contribute to the learning disabilities that are common in people with NF1 (see Chapter 8) .
Although questions remain about exactly how neurofibromin regulates Ras, the fact that overactive Ras expression is linked to many manifestations of NF1 provides fertile ground for research. As scientists learn more about the pathophysiology of NF1, and what role Ras and other molecules play, new targets for therapy may be identified.
The cAMP-PKA Pathway
The GAP-related domain of the NF1 gene comprises only 10% of its entire coding region. 21(p749) This suggests that the gene may have other functions besides regulating the Ras pathway. 16(p601) One of the other signaling pathways that neurofibromin may regulate is known as the cAMP-PKA pathway (short for cyclic adenosine 3',5'-monophosphate-protein kinase A). Some of the strongest evidence for this theory comes from experiments done in fruit flies, which suggest that neurofibromin regulation of the cAMP-PKA pathway influences the action of neurons in the brain and may provide another mechanism through which neurofibromin defects contribute to NF1 learning disabilities 18(p16) (see Chapter 8) . Experiments in mice have indicated that a reduction in neurofibromin levels affects how responsive Schwann cells are to cAMP. This is significant because an overproliferation of Schwann cells contributes to neurofibroma formation in NF1. Although scientists are still trying to connect all the dots, it is thought that neurofibromin loss, PKA signaling, and levels of cAMP are somehow related. 21(p749) Although the research continues, it may be that neurofibromin regulates cell proliferation and other cell activities not only by working through the Ras pathway, but also by working through the cAMP-PKA pathway, and possibly other cell signaling pathways.
N How NF1 Gene Mutations May Cause Manifestations
As mentioned earlier in this chapter, a leading theory is that the NF1 gene functions as a tumor suppressor. That gives rise to the questions of how it regulates cell growth, and why a mutation leads to tumor growth in NF1. Several mechanisms of action have been proposed, depending on the type of tumor. Just why manifestations develop depends in part on whether one or both copies of the NF1 gene are mutated. If both copies of the NF1 gene are mutated (the "second hit" in Knudson's tumor suppressor theory), the resulting loss of neurofibromin leads to abnormal cell growth following the classic tumor suppressor model. Second hits are evident in tissue taken from malignant tumors in NF1 patients, such as pheochromocytomas and malignant peripheral nerve sheath tumors, [22] [23] [24] as well as in benign neurofibromas. Other evidence suggests that a reduction in neurofibromin to less-than-normal levels (a situation known as haploinsufficiency) may contribute to many nontumor manifestations of NF1, such as café-au-lait spots, bone deformities, and cognitive impairments. 16(p601) To further complicate the picture, factors such as hormones and other genes may themselves modify or enhance neurofibromin's own effects in cells. This would help to explain why manifestations of NF1 vary so much, even among siblings who inherit the same genetic mutation. 16(p593) This theory is attractive because tumors tend to form only after multiple "hits" to various genes. Many cancers, for instance, involve the loss of a DNA repair mechanism, the transformation of a normal gene into an oncogene, and the malfunctioning of a tumor suppressor gene. Still another reason for variability is chance: severity of manifestations may depend on whether a second hit occurs in a given nerve at a specific time during development.
N Pathogenesis of Tumors Neurofibromas
One of the most common manifestations in NF1, the growth of neurofibromas, is also one of the most complicated. When scientists analyze tissue from different NF1 tumor types, they find evidence of loss of heterozygosity (the "second hit") in malignant peripheral nerve sheath tumors, which develop from plexiform neurofibromas; second hits are also evident in benign neurofibromas. [25] [26] [27] [28] [29] [30] Development of genetically engineered chimeric mice have provided an animal model showing that loss of heterozygosity is required for neurofibroma formation. 31 Subsequent research revealed that a "second hit" in a Schwann cell is the initiating event, but that neurofibromas form only if there is NF1 haploinsufficiency in surrounding cells. 32 These other cells may be responsive to the aberrant cell's signaling or may be sensitive to the specific loss of neurofibromin. 16(p596) In any event, neurofibroma formation is a coordinated process that involves not only the initiating Schwann cell but also neighboring cells. As the Schwann cell begins to divide abnormally, it influences other Schwann cells (which seem particularly sensitive to neurofibromin levels) as well as other supportive cells: perineural cells, mast cells, fibroblasts, and neurons (Figs. 3-6 and 3-7) . When the perineural cells become involved, they not only proliferate in excess but also disrupt the diffusion barrier, a sort of protective structure that keeps circulating hormones and growth factors at bay. Once the barrier is disrupted, however, these molecules can themselves encourage more cell growth, only further fueling the out-ofcontrol proliferation. 
Optic Gliomas
Gliomas are tumors that develop from glial cells in the brain. Typically these are benign and develop on the optic nerve leading from the eye to the brain. It is not yet clear what factors contribute to the development of gliomas, but neurofibromin appears to play a role, albeit one that is slightly different from its contribution to neurofibroma development. One theory is that neurofibromin loss somehow initiates tumor development-a theory that is supported by laboratory experiments that show that when one NF1 gene is mutated, thereby reducing neurofibromin expression, astrocyte proliferation increases. [33] [34] [35] Another theory is that gliomas develop because neurofibromin loss in these cells disrupts the normal response to injury. Although normally expressed at low levels in astrocytes, neurofibromin is sometimes overexpressed in response to an injury that interrupts blood flow to the brain (known medically as ischemia). 36 If the NF1 gene is defective, however, neurofibromin may not be able to function, and enzymes and cells released during an inflammatory response may themselves spark astrocytoma proliferation.
16(p600)
Malignant Peripheral Nerve Sheath Tumors
Five to ten percent of people with NF1 develop malignant peripheral nerve sheath tumors (MPNSTs), which are believed to originate for the most part in plexiform neurofibromas. 37 Analysis of tissue from these tumors indicates that in addition to sustaining mutations in both copies of the NF1 gene, additional mutations and second hits have been sustained by other genes, primarily the p53 tumor suppressor gene 38, 39 and two other tumor suppressors, p16INK4a and p14ARF. [40] [41] [42] Taken together with studies in mice, the evidence suggests that p53 and the NF1 genes must both be completely inactivated and then spark a cascade of other biological events that initiate MPNST development. 16(p599) It may well be that other genes interact with the NF1 gene to create malignancies in people with NF1.
N Additional Physical Manifestations
The earliest manifestations of NF1 include café-au-lait spots, skinfold freckling, and Lisch nodules. All of these manifestations involve abnormalities of cells derived from the neural crest early in embryonic development. Abnormalities in melanocytes, for instance, contribute to the darker pigmentation in both café-au-lait spots and Lisch nodules. The chromaffin cells, located in the adrenal medulla (part of the endocrine system), sometimes give rise to pheochromocytomas.
Laboratory experiments have shown that cells derived from the neural crest are sensitive to fluctuations in neurofibromin. They behave aberrantly, even under conditions of haploinsufficiency, when one NF1 gene is mutated. Sometimes the effects are indirect. Studies in mice, for instance, suggest that reduced levels of neurofibromin have other downstream effects that can cause changes in coat color. 43 
N Theories of Pathogenesis in NF2
NF2 Gene Structure, Mutations, and Expression
The NF2 gene (Fig. 3-8 ) consists of 110,000 chemical bases.
14(p351) The gene encodes for a protein that one team named "merlin" (for moesin-, ezrinand radixin-like protein). 4 The other team called the protein "schwannomin" because, when it functions normally, it prevents the development of the hallmark NF2 tumor. 5 Two different versions of the NF2 protein can be produced, depending on circumstances and location in the body, because one exon is alternatively spliced. 14(p351) Many different types of mutations have been identified in the NF2 gene, across most exons in the gene. These are summarized in Table 3 -2. There is no one "hot" spot where mutations occur more frequently than in other areas. Most inherited mutations have the effect of truncating the protein in one of several ways, 14(p353) resulting in significant reduction in protein available to cells. The NF2 gene is expressed throughout the body in many different types of cells, including neurons and glial cells such as Schwann cells, fibroblasts, and meningioma cells. 
NF2 Gene Signaling Pathways
Although the NF2 gene is classified as a tumor suppressor, its protein product appears to regulate cell proliferation indirectly, by affecting cellto-cell signals, and by the interaction between cells and surrounding tissue known as the extracellular matrix. The gene also appears to activate and interact with several signaling pathways. Insights into merlin's function started when researchers realized that the NF2 gene sequence resembles members of a family of proteins that affect the interactions of cells and the cytoskeleton, a complex set of structures within the cell. This family includes erythrocyte protein 4.1, moesin, ezrin, radixin, and talin, none of which is associated with regulation of cell proliferation or tumor formation. Instead, these proteins regulate interactions with the cytoskeleton to determine cell shape, movement, division, and cell-to-cell communication. This finding was unexpected, and it suggested that the NF2 gene might represent a new type of tumor suppressor. 4 Although merlin interacts with several other proteins, its signaling pathways have not yet been well defined. One theory is that merlin may interact with another protein, known as Expanded (a member of the 4.1 protein family), to control cell proliferation. 47 Another theory is that the NF2 gene may function as a "gatekeeper" gene that helps to regulate basic functions in a cell, such as division and proliferation, differentiation, and programmed cell suicide or apoptosis. 21(pp751,752) Presumably, then, a mutation in the NF2 gene, which causes a defect in or loss of its protein product, might result in a disruption of the normally harmonious interactions between cells, and between cells and the surrounding matrix. This could, in turn, indirectly disrupt cellular proliferation. 5(p521) Normally cells continue to divide, for instance, until they encounter other cells-a phenomenon known as contact inhibition. If this inhibition were lost because the NF2 gene caused disruptions in the cell-matrix communication network, then these cells would begin to multiply out of control.
Neurofibromatosis
N How NF2 Gene Mutations May Cause Tumors
In addition to the inherited NF2 gene mutation, researchers have also found additional "second hits" to the gene in tumor tissue from people with the disorder. This confirms that the NF2 gene functions as a tumor suppressor and that tumor formation is initiated when it is mutated. However, in some types of tumors, other genes or factors may participate in the process.
Schwannomas
Bilateral vestibular schwannomas affect almost everyone with NF2, although sometimes the tumors develop in only one ear. Analysis of schwannoma tumor tissue reveals that, as expected, both copies of the NF2 gene are mutated in all samples taken from people with the familial form of NF2. Both copies of the gene are also mutated in schwannomas in most people with the sporadic form of the disorder. 21(p752) Clearly, then, merlin functions as a tumor suppressor that prevents the development of schwannomas.
Meningiomas
These brain tumors occur less frequently than schwannomas in people with NF2, but they are the second most common type of tumor in the disorder. Double-hit NF2 gene mutations are found in all meningiomas taken from people with the familial form of the disorder, and in 30 to 70% of sporadic meningiomas. 21(p752) At least one study has reported, however, that some familial meningiomas do not show evidence of a second hit to the NF2 gene, suggesting that some other tumor suppressor gene may prevent these tumors from forming. 48 
Other Tumors
Less is known about the status of NF2 mutations in other types of NF2-related tumors, such as ependymomas, astrocytomas, and gliomas. The research in this area continues.
